CN118496313A - 钙敏感受体激动剂化合物及其应用 - Google Patents

钙敏感受体激动剂化合物及其应用 Download PDF

Info

Publication number
CN118496313A
CN118496313A CN202410744948.1A CN202410744948A CN118496313A CN 118496313 A CN118496313 A CN 118496313A CN 202410744948 A CN202410744948 A CN 202410744948A CN 118496313 A CN118496313 A CN 118496313A
Authority
CN
China
Prior art keywords
peptide
arg
conjugate group
compound
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410744948.1A
Other languages
English (en)
Chinese (zh)
Inventor
吴方舟
张瑾
高菲
吴然
廖成
王雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Beijing Tuojie Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuojie Biomedical Technology Co ltd filed Critical Beijing Tuojie Biomedical Technology Co ltd
Publication of CN118496313A publication Critical patent/CN118496313A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202410744948.1A 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用 Pending CN118496313A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019112500881 2019-12-09
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用
CN202080057062.XA CN114222578B (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080057062.XA Division CN114222578B (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
CN118496313A true CN118496313A (zh) 2024-08-16

Family

ID=76328843

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410744948.1A Pending CN118496313A (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用
CN202080057062.XA Active CN114222578B (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080057062.XA Active CN114222578B (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Country Status (11)

Country Link
US (1) US20230041996A1 (cg-RX-API-DMAC7.html)
EP (1) EP4091623A4 (cg-RX-API-DMAC7.html)
JP (1) JP7796013B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110789A (cg-RX-API-DMAC7.html)
CN (2) CN118496313A (cg-RX-API-DMAC7.html)
AU (1) AU2020399030B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022011127A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159744A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006892A (cg-RX-API-DMAC7.html)
TW (1) TW202122410A (cg-RX-API-DMAC7.html)
WO (1) WO2021115272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117295510A (zh) * 2021-06-08 2023-12-26 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
TW202313655A (zh) * 2021-06-08 2023-04-01 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物的鹽酸鹽及醫藥組成物和其應用
CN121378400A (zh) * 2024-10-24 2026-01-23 成都诺和晟泰生物科技有限公司 一种多肽化合物、包含其的组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
CN103270018A (zh) * 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
WO2012069421A1 (en) * 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
PT2717896T (pt) * 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
MX355063B (es) * 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.

Also Published As

Publication number Publication date
US20230041996A1 (en) 2023-02-09
AU2020399030A1 (en) 2022-06-23
KR20220110789A (ko) 2022-08-09
EP4091623A1 (en) 2022-11-23
CN114222578B (zh) 2024-06-25
TW202122410A (zh) 2021-06-16
EP4091623A4 (en) 2024-01-03
CA3159744A1 (en) 2021-06-17
MX2022006892A (es) 2022-10-07
WO2021115272A1 (zh) 2021-06-17
BR112022011127A2 (pt) 2022-08-23
CN114222578A (zh) 2022-03-22
JP7796013B2 (ja) 2026-01-08
AU2020399030B2 (en) 2026-04-09
JP2023504904A (ja) 2023-02-07

Similar Documents

Publication Publication Date Title
CN114222578B (zh) 钙敏感受体激动剂化合物及其应用
AU2004251616A1 (en) Melanocortin receptor 4(MC4) agonists and their uses
US11766470B2 (en) Manufacture, formulation and dosing of apraglutide
CA3091993A1 (en) Compstatin analogues and their medical uses
CN103242441A (zh) 一种齐考诺肽的固相合成方法
AU673431B2 (en) Motilin-like polypeptides that inhibit gastrointestinal motor activity
AU2009246059A1 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US20040122013A1 (en) Analogs of nocicettin
WO2022257940A1 (zh) 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
EP1997826A2 (en) Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them
EP4137502A1 (en) Vipr2 antagonist peptide
HK40069562A (en) Calcium-sensing receptor agonist compound and application thereof
RU2827834C1 (ru) Соединение, представляющее собой агонист кальций-чувствительного рецептора, и его применение
HK40069562B (en) Calcium-sensing receptor agonist compound and application thereof
CN117295510A (zh) 一种钙敏感受体激动剂的组合物及其应用
CN115057910A (zh) 补体活性调节剂,其制备方法及医药用途
CN121758557A (zh) 一种补体活性调节剂,其制备方法及医药用途
JP2026505364A (ja) Tnf-アルファ結合剤およびそれを使用する方法
TW201233394A (en) TFPI inhibitors and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20241030

Address after: 200245 No. 279, Wen Jing Road, Shanghai, Minhang District

Applicant after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Country or region after: China

Address before: 102206 floor 7, building 4, hospital 9, medical Road, Life Science Park, Changping District, Beijing

Applicant before: Beijing tuojie Biomedical Technology Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right